CompletedNCT00110461
Two aripiprazole doses for mania in young people with bipolarity
About this title
Aripiprazole in Children and Adolescents With Bipolar I Disorder
Read the official source — NCT00110461Medication studyAges 10–17United States
Understand this study
Who was this study for?
Listed age limits: 10 years to 17 years.
- Listed locations
- Scottsdale and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 296
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00110461
- Official title
Show the full official title
A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale · Little Rock · National City
49 more locations
- Orange
- Pasadena
- Sacramento
- San Diego
- Stanford
- Washington D.C.
- Altamonte Springs
- Hialeah
- Jacksonville
- Miami
- North Miami
- Tampa
- Atlanta
- Smyrna
- Boise
- Chicago
- Libertyville
- Indianapolis
- Kansas City
- Newton
- Lexington
- Baton Rouge
- Lake Charles
- Shreveport
- Cambridge
- Medford
- Clinton Township
- Rochester Hills
- St Louis
- Las Vegas
- Elmsford
- New York
- Rochester
- Stony Brook
- Cincinnati
- Cleveland
- Oklahoma City
- Philadelphia
- Charleston
- Memphis
- Bellaire
- Fort Worth
- Houston
- San Antonio
- Herndon
- Richmond
- Kirkland
- Spokane
- Milwaukee
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and placebo.
Who was this study for?
Listed age limits: 10 years to 17 years.
